Two mechanistic oncology studies identify non‑tumor drivers of metastasis. Rasbach et al. showed that a tumor‑intrinsic ITGB2 axis can be inhibited to suppress melanoma growth, revealing adhesion pathways as therapeutic targets (note: related to melanoma). In lung cancer-focused work, cancer‑associated fibroblasts (CAFs) were found to secrete superoxide dismutase 3 (SOD3), which promotes vascular remodeling and metastasis in lung adenocarcinoma. Separately, Jiang and colleagues linked HDAC6 activity to enhanced metastasis and immune suppression in lung cancers, suggesting HDAC6 inhibitors could reverse immune evasion. Collectively, these studies emphasize stromal and epigenetic modulators as avenues for anti‑metastatic strategies.